Naresh Tanna
Chief of Staff to CEO and Head of Investor Relations
Naresh Tanna brings more than 20 years of biopharmaceutical experience leading the commercialization of multiple blockbuster drug launches. He has a proven track record of successfully developing assets in early-to-late phase clinical studies and subsequently launching innovative wholly owned and/or partnered medicines across numerous therapeutic areas including hematology, oncology, infectious diseases, and rare diseases.
Since joining Precision in 2022, Naresh has been an integral member of the Senior Leadership Team helping to drive Precision’s corporate strategy into fruition as it advances its wholly owned in vivo gene editing programs through clinic. Additionally, Naresh leads all aspects of corporate communications with our investors and other important stakeholders. Previously, Naresh has held roles at high growth companies like Celgene, ImClone Systems, Amgen, AbbVie, and Lilly as well as life sciences consulting roles at Trinity Partners and Clarkston Consulting. Naresh holds an M.B.A. from the IESE Business School and a B.S. in Biomedical Engineering and Political Science from Rutgers School of Engineering.